Baars J W, Coenen J L, Wagstaff J, van der Valk P, Pinedo H M
Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
Br J Cancer. 1992 Oct;66(4):698-9. doi: 10.1038/bjc.1992.340.
Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.
白细胞介素-2（IL-2）目前已在多个欧洲国家注册用于治疗肾细胞癌。皮下（sc）给药途径的使用越来越多，因为与高剂量静脉内（iv）方案相比，其毒性特征更好。我们在此报告一名患者，该患者在皮下注射IL-2的部位发生了小叶性脂膜炎，导致皮下治疗无法继续。随后通过静脉注射给予相同剂量的IL-2导致该问题再次出现，再次需要停止IL-2治疗。
